AZACITIDINE
NICE Appraisal
DSU Reports
Myelodysplastic syndromes – azacitidine: Review of Celgene’s response to the post-appeal ACD (December 2010)
Addendum to the September 2010 report by the Decision Support Unit (October 2010)
Myelodysplastic syndromes – Azacitidine: A critical appraisal of additional evidence submitted by Celgene and the MDS Foundation (September 2010)
Azacitidine STA Economic Model (September 2009)
DSU response to manufacturer’s revised model (December 2009)